Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Fineline Cube Dec 14, 2025
Company Deals

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

Fineline Cube Dec 14, 2025
Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Fineline Cube Dec 14, 2025
Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Fineline Cube Dec 14, 2025
Company Drug

FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment

Fineline Cube Nov 30, 2022

US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA)...

Company

Sino Biological to Invest RMB 1 Billion in Beijing Bio-Pharmaceutical Park

Fineline Cube Nov 30, 2022

Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140...

Company Drug

Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment

Fineline Cube Nov 29, 2022

China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine...

R&D

Hong Kong Researchers Identify New Target for Epilepsy Treatment

Fineline Cube Nov 29, 2022

Researchers at the University of Hong Kong have published the results of a study that...

Company Drug

Hope Medicine Gains Global Approval for Phase II Trial of HMI-115

Fineline Cube Nov 29, 2022

China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...

Company Deals

Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline

Fineline Cube Nov 29, 2022

Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...

Policy / Regulatory

NMPA Launches Electronic Certificates for API and Pharmaceutical Product Exports

Fineline Cube Nov 29, 2022

The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two...

Company Deals

I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies

Fineline Cube Nov 29, 2022

China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to...

Company Deals

Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round

Fineline Cube Nov 29, 2022

China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...

Company

Alibaba Health Reports 22.9% Revenue Growth in H1 2022

Fineline Cube Nov 29, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...

Company Deals

3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million

Fineline Cube Nov 29, 2022

China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO)...

Company Policy / Regulatory

China’s Medical Product Trade Surplus Declines Amid COVID-19 Impact

Fineline Cube Nov 28, 2022

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Nuance Pharma Partners with DKSH to Launch Bentrio Nasal Spray in Hong Kong and Macau

Fineline Cube Nov 28, 2022

China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to...

Deals

Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement

Fineline Cube Nov 28, 2022

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...

Company Drug

Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC

Fineline Cube Nov 28, 2022

Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...

Company Deals

ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round

Fineline Cube Nov 28, 2022

China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB...

Company

Ascentage Pharma Receives Drug Production License for Suzhou Plant

Fineline Cube Nov 28, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...

Company Drug

Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea

Fineline Cube Nov 28, 2022

China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...

Company

Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo

Fineline Cube Nov 28, 2022

The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine...

Company Deals

Huadong Medicine Partners with Dongyang Med for Equity Collaboration

Fineline Cube Nov 28, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang...

Posts pagination

1 … 525 526 527 … 597

Recent updates

  • Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
  • Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
  • Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
  • InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
  • InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Company Deals

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.